Who are D-Mannitol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aridol Kit, Aridol Kit, Aridol Kit, Mannitol, Aridol Kit, mannitol 20% intravenous fluid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/d-mannitol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

D-Mannitol — Competitive Intelligence Brief

D-Mannitol (D-Mannitol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Osmotic diuretic. Area: Neurology.

phase 2 Osmotic diuretic Neurology Small molecule Live · refreshed every 30 min

Target snapshot

D-Mannitol (D-Mannitol) — Thiogenesis Therapeutics, Inc.. D-Mannitol is an osmotic agent that draws fluid into the intracellular space to reduce intracranial pressure and improve cellular hydration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
D-Mannitol TARGET	D-Mannitol	Thiogenesis Therapeutics, Inc.	phase 2	Osmotic diuretic
Aridol Kit	MANNITOL	Baxter	marketed	Osmotic Diuretic [EPC]	sodium channels	1964-01-01
Aridol Kit	Mannitol	Baxter	marketed	Osmotic diuretic	Glomerular filtrate osmolarity; tubular reabsorption of water	1964-01-01
Aridol Kit	Mannitol	Baxter	marketed	Osmotic diuretic	Glomerular filtrate osmolarity; tubular reabsorption of water	1964-01-01
Mannitol	Mannitol	Baxter	marketed	Osmotic diuretic	Glomerular filtrate osmolarity; intracellular water movement	1964-01-01
Aridol Kit	Mannitol	Baxter	marketed	Osmotic diuretic	Glomerular filtrate osmolarity; tubular reabsorption of water	1964-01-01
mannitol 20% intravenous fluid	mannitol 20% intravenous fluid	Ain Shams University	marketed	Osmotic diuretic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Osmotic diuretic class)

Baxter · 4 drugs in this class
Centre Hospitalier Universitaire de Besancon · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Thiogenesis Therapeutics, Inc. · 1 drug in this class
University Hospital, Grenoble · 1 drug in this class
University Hospital, Saarland · 1 drug in this class
Ain Shams University · 1 drug in this class
University of Aarhus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). D-Mannitol — Competitive Intelligence Brief. https://druglandscape.com/ci/d-mannitol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab